A Pharmacokinetic Study to Evaluate the Bioequivalence of a Test Formulation Compared to an Equivalent Dose of a Reference Drug Product

Inclusion Criteria: 1. Healthy adult, aged between 20 to 40 years old. 2. Physically and mentally healthy subjects as confirmed by an interview, medical history, clinical examination, laboratory tests, chest x-ray and electrocardiogram. 3. The normal range of the body mass index should between 18.5 and 25. 4. Normal laboratory determinations results including: SGOT (AST), SGPT (ALT), albumin, glucose, creatinine, uric acid, cholesterol, TG, γ-GT, alkaline phosphatase, total bilirubin, BUN, HBsAg, Anti-HCV and Anti-HIV test. 5. Normal hematology results including: hemoglobin, hematocrit, WBC count with differential, RBC count and platelet count. 6. Normal urinalysis results including: glucose, protein, RBC, WBC, epith, casts and bacteria. 7. Female subject who is: * using adequate contraception since last menstruation and no plan for conception during the study. * non-lactating. * has negative pregnancy test (urine) within 14 days prior to the study. 8. Informed consent form signed. Exclusion Criteria: 1. A history of drug or alcohol abuse during the past 24 weeks. 2. Sensitivity to analogous drug. 3. A clinically significant illness (such as significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis, melaena or gastric ulcer) within the past 4 weeks. 4. Evidence of any clinical significant renal, cardiovascular, hepatic, hematopoetic, neurological, pulmonary or gastrointestinal pathology within the past 4 weeks. 5. Planed vaccination during the time course of the study. 6. Participation of any clinical investigation during the last 60 days. 7. Regular use of any medication during the last 4 weeks. 8. Single use of any medication during the last 2 weeks. 9. Blood donation of more than 250 mL within the past 12 weeks. 10. Individuals are judged by the investigator or co-investigator to be undesirable as subjects.